VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia

Blood

Volumn 103, Issue 6, 2004, Pages 2276-2283

  Egle, Alexander ^a   Harris, Alan W ^a   Bath, Mary L ^a   O'Reilly, Lorraine ^a   Cory, Suzanne ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN BCL 2; VAV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENE LOCUS; GENE MUTATION; GERMINAL CENTER; KIDNEY DISEASE; LYMPH NODE HYPERPLASIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; T LYMPHOCYTE;

EID: 1542283724     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2469     Document Type: Article

References (39)

1. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097-1099.
2. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41:899-906.
3. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19-28.
4. Ladanyi M, Wang S. Detection of rearrangements of the BCL2 major breakpoint region in follicular lymphomas. Correlation of polymerase chain reaction results with Southern blot analysis. Diagn Mol Pathol. 1992;1:31-35.
5. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
6. McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79-88.
7. Strasser A, Harris AW, Vaux DL, et al. Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr Top Microbiol Immunol. 1990;166:175-181.
8. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature. 1991;349:254-256.
9. Strasser A, Harris AW, Cory S. Eμ-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene. 1993;8:1-9.
10. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A. 1994;91: 8910-8914.
11. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 1995;85:2528-2536.
12. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002;99:282-289.
13. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A. 1999;96: 14943-14948.
14. Han WR, Zhan Y, Murray-Segal LJ, Brady JL, Lew AM, Mottram PL. Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice. Transplantation. 2000;70:168-174.
15. Strasser A, Elefanty AG, Harris AW, Cory S. Progenitor tumours from Eμ-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 1996;15:3823-3834.
16. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990; 137:225-232.
17. O'Reilly LA, Huang DCS, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 1996;15: 6979-6990.
18. O'Reilly LA, Harris AW, Tarlinton DM, Corcoran LM, Strasser A. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J Immunol. 1997; 159:2301-2311.
19. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim requ red for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286:1735-1738.
20. Wang Z, Raifu M, Howard M, et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the cesign of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods. 2000;233:167-177.
21. Rogerson BJ. Mapping the upstream boundary of somatic mutations in rearranged immunoglobulin transgenes and endogenous genes. Mol Immunol. 1994;31:83-98.
22. Strasser A, Harris AW, Cory S. The role of bcl-2 in lymphoid differentiation and transformation. Curr Top Microbiol Immunol. 1992;182:299-302.
23. Fredrickson TN, Harris AW. Atlas of Mouse Hematopathology. Amsterdam: Harwood Academic; 2000.
24. Morse HC 3rd, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100:246-258.
25. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991;88: 8661-8665.
26. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 1991;67:889-899.
27. - T cell progenitors. Int Immunol. 1997;9:1291-1301.
28. Hildeman DA, Zhu Y, Mitchell TC, et al. Activated T cell death in vivo mediated by pro-apoptotic Bcl-2 family member, Bim. Immunity. 2002;16: 759-767.
29. Bouillet P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002;415: 922-926.
30. Poppema S, Kaleta J, Hugh J, Visser L. Neoplastic changes involving follicles: morphological, immunophenotypic and genetic diversity of lymphoproliferations derived from germinal center and mantle zone. Immunol Rev. 1992;126:163-178.
31. Levy R, Levy S, Cleary ML, et at. Somatic mutation in human B-cell tumors. Immunol Rev. 1987; 96:43-58.
32. Levy S, Mendel E, Kon S, Avnur Z, Levy R. Mutational hot spots in Ig V region genes of human follicular lymphomas. J Exp Med. 1988;168:475-489.
33. Dighiero G, Hart S, Lim A, Borche L, Levy R, Miller RA. Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood. 1991;78:581-585.
34. Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R. Ig VH gene expression among human follicular lymphomas. Blood. 1991;78:1561-1568.
35. Dighiero G. Autoantibody activity and V gene usage by B-cell malignancies. Leuk Lymphoma. 1992;8:345-351.
36. Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med. 1992;176:1137-1148.
37. Kuo P, Alban A, Gebhard D, Diamond B. Overexpression of bcl-2 alters usage of mutational hot spots in germinal center B cells. Mol Immunol. 1997;34:1011-1018.
38. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science. 1998;280:1750-1752.
39. Muschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Kuppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med. 2000;192: 1833-1840.